根据《中华人民共和国证券法（2019 年修订）》《上海证券交易所股 票上市规则（2023 年修订）》和《上海证券交易所上市公司自律监管指南 第 1 号——公告格式》（2023 年修订）》等相关法律法规，作为漳州片仔 癀药业股份有限公司的董事、监事和高级管理人员，我们在全面了解和审 核《公司 2023 年第三季度报告》后，发表意见如下： 漳州片仔癀药业股份有限公司 董事、监事和高级管理人员 漳州片仔癀药业股份有限公司董事、监事和高级管理人员 关于公司 2023 年第三季度报告的确认意见 2023 年 10 月 16 日 1、 公司严格按照股份制公司的财务制度规范运作，公司 2023 年第 三季度报告的编制符合法律、行政法规、《漳州片仔癀药业股 份有限公司章程》及公司内部管理制度的各项规定，《公司 2023 年第三季度报告》公允、真实、全面地反映了公司 2023 年第三 季度的财务状况和经营成果。 2、 公司第七届董事会第十五次会议、第七届监事会第十次会议审 议通过《公司 2023 年第三季度报告》的议案。 3、 公司全体董事、监事和高级管理人员保证《公司 2023 年第三季 度报告》所披露的信息真实、准确、完整 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached CNY 5,045,275,709.94, representing a 14.08% increase compared to CNY 4,422,632,056.64 in the same period last year[12]. - Net profit attributable to shareholders for the first half of 2023 was CNY 1,540,837,053.29, up 17.23% from CNY 1,314,364,302.27 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was CNY 1,577,264,060.05, reflecting a 19.80% increase from CNY 1,316,611,524.12 in the same period last year[12]. - Basic earnings per share for the first half of 2023 were CNY 2.55, up 16.97% from CNY 2.18 in the same period last year[13]. - The company reported a total profit of ¥1,861,157,111.49, compared to ¥1,597,624,302.34 in the same period last year, marking a growth of 16.4%[100]. - The total comprehensive income for the first half of 2023 was ¥1,598,392,363.53, compared to ¥1,267,092,706.30 in the previous year, reflecting a growth of 26.1%[102]. Cash Flow and Financial Position - The company's net cash flow from operating activities decreased by 74.49%, amounting to CNY 1,368,609,738.45 compared to CNY 5,364,583,037.99 in the previous year[12]. - The company reported a significant increase in non-operating income by 157.00% to ¥1,829,433.43, driven by government subsidies and other gains[34]. - The company experienced a 1,753.88% decrease in net cash flow from financing activities, primarily due to reduced cash received from borrowings[36]. - The total cash inflow from operating activities was ¥2,280,492,801.51, down from ¥6,013,353,115.18 year-on-year[109]. - The company reported a net cash outflow from investment activities of ¥494,735,901.98, compared to a larger outflow of ¥5,212,896,238.65 in the previous year[109]. Assets and Liabilities - As of June 30, 2023, the net assets attributable to shareholders were CNY 12,129,601,206.27, a 7.06% increase from CNY 11,329,967,292.12 at the end of the previous year[12]. - Total assets increased by 8.92% to CNY 15,907,148,751.88 from CNY 14,603,844,518.45 at the end of the previous year[12]. - The company's total liabilities reached CNY 3,239,112,379.36, compared to CNY 2,779,905,281.31 at the end of 2022, marking an increase of around 16.5%[96]. - The company's total current liabilities amounted to CNY 2,970,582,277.19, up from CNY 2,510,181,610.40, indicating an increase of about 18.3%[96]. Industry Context - The pharmaceutical manufacturing industry saw a revenue decline of 2.9% year-on-year, totaling 1,249.6 billion RMB in the first half of 2023[17]. - The total profit for the pharmaceutical manufacturing industry decreased by 17.1% year-on-year, amounting to 179.45 billion RMB[17]. Product Development and Innovation - The company has not disclosed any new product developments or market expansion strategies in this report[14]. - The company is advancing over 10 clinical research projects related to its core product, Pian Zai Huang, focusing on liver disease, tumors, and antiviral treatments[24]. - Three Class 1 chemical new drugs and three Class 1.1 traditional Chinese medicine new drugs are currently in clinical research stages, indicating a robust pipeline for future product offerings[24]. - The company aims to strengthen its core position in the health sector by focusing on the development of its Pian Zai Huang series of products, cosmetics, and health foods[22]. Market Presence and Brand Value - The company has established strategic partnerships with over 10,000 retail stores through collaborations with major chain pharmacies, enhancing its market presence across key regions such as Fujian, Guangdong, and Beijing[22]. - The brand value of the company's "Pian Zai Huang" reached 40.937 billion CNY, ranking first in the "Hurun Brand List for Medical Health Brands" for two consecutive years (2021-2022) and second in the "Chinese Time-honored Brand" category[21]. Environmental and Social Responsibility - The company emphasizes environmental protection and compliance with new regulations, implementing measures to reduce environmental risks and enhance sustainability practices[59]. - The company actively supports the "Healthy China" national strategy and has established a precision poverty alleviation demonstration base in collaboration with Taibai County and Ning Shan County, providing technical support and funding to local farmers[81]. - During the reporting period, the company donated a total of 690,000 RMB to various charitable causes, including 200,000 RMB for children with severe illnesses and 400,000 RMB for educational support[81]. Governance and Compliance - The company held two shareholder meetings in 2023, with all proposed resolutions approved, indicating strong governance[62]. - The financial statements were approved by the board on August 17, 2023, ensuring compliance with accounting standards[119]. - The company has undergone changes in its board of directors, with new independent directors elected to strengthen governance[64].

漳州片仔癀药业股份有限公司 漳州片仔癀药业股份有限公司董事、监事和高级管理人员 关于公司 2023 年半年度报告的确认意见 根据《中华人民共和国证券法（2019 年修订）》《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》（2021 年修订）》和《上海证券交易所股票上市规则（2023 年修订）》等相关规 定和要求，作为漳州片仔癀药业股份有限公司的董事、监事和高级管理人 员，我们在全面了解和审核《公司 2023 年半年度报告》后，发表意见如 下： 董事、监事和高级管理人员 2023 年 8 月 17 日 1、 公司严格按照股份制公司的财务制度规范运作，公司 2023 年半 年度报告的编制符合法律、行政法规、《漳州片仔癀药业股份 有限公司章程》及公司内部管理制度的各项规定，2023 年半年 度报告公允、真实、全面地反映了公司 2023 年半年度报告的财 务状况和经营成果。 2、 公司第七届董事会第十四次会议、第七届监事会第九次会议审 议通过《公司 2023 年半年度报告及摘要》的议案。 3、 公司全体董事、监事和高级管理人员保证《公司 2023 年半年度 报告及摘要》所披露的信息真 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-026 审计委员会：贾建军（主任委员）、杜守颖、赖文宁 提名委员会：李广培（主任委员）、林纬奇、范志鹏、杜守颖 1 / 2 漳州片仔癀药业股份有限公司 关于调整董事会专门委员会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）原独立董事 贾建军先生、李广培先生于2017年8月起，连任公司独立董事时间达 到六年，任期届满。上述两位独立董事向公司董事会提请辞去独立董 事及董事会下属专门委员会相关职务。公司于2023年5月22日召开第 七届董事会第十一次会议，审议通过《公司关于选举独立董事的议 案》，会议增补陈蕾女士、张磊先生为公司第七届董事会独立董事候 选人，并经2023年6月15日的2022年年度股东大会审议通过。 公司原董事长林纬奇先生因工作调整，向董事会辞去公司董事、 董事长及董事会下属专门委员会委员等职务。公司于2023年7月24日 召开第七届董事会第十二次会议，审议通过《公司关于增补董事的议 案》，会议增补林 ...

表决结果：8 票同意，0 票反对，0 票弃权。 证券代码：600436 证券简称：片仔癀 公告编号：2023-025 漳州片仔癀药业股份有限公司 第七届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届董事 会第十三次会议于 2023 年 8 月 9 日（星期三）下午 16:30 以现场与 通讯相结合方式在芗江酒店一楼芗江 A 厅会议室召开。会议通知和议 案以专人送达、电子邮件方式发出。本次会议应参加表决董事 8 人， 实际表决董事 8 人。经全体董事同意，本次会议豁免通知时限要求。 经半数以上董事推举，会议由董事林志辉先生主持。本次会议召开符 合《公司法》与《漳州片仔癀药业股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，合法、有效。到会董事以通讯方式表决， 审议以下议案： 一、 审议通过《公司关于选举董事长的议案》； 特此公告。 漳州片仔癀药业股份有限公司 董 事 会 为规范公司运作，完善法人治理结构，根据《公司章程》等相关 规定，董事 ...

泰和泰证字[2023]PZH-02 号 泰和泰（北京）律师事务所 北京市朝阳区东四环中路 56 号远洋国际中心 A 座 12 层 电话：（010）85865151 传真：（010）85861922 邮政编码：100025 泰和泰（北京）律师事务所关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会法律意见书 泰和泰（北京）律师事务所 关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会 法律意见书 泰和泰（北京）律师事务所 关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会法律意见书 泰和泰证字[2023]PZH-02 号 致：漳州片仔癀药业股份有限公司 泰和泰（北京）律师事务所（以下简称"本所"）接受漳州片仔癀药业股份 有限公司（以下简称"公司"）的委托，指派许军利律师、殷庆莉律师对公司 2023 年第一次临时股东大会（以下简称"本次股东大会"）进行见证，并依据 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东大会规则》（以下简称"《股东大会规则》"）、《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》（以下简称"《规范运 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-024 漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 369 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 413,149,793 | | 3、出席会议的股东所持有表决权股份数占公司有表 | 68.4797 | | 决权股份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主 持情况等。 1 (一) 股东大会召开的时间：2023 年 8 月 9 日 (二) 股东大会召开的地点：漳州市芗城区漳州芗江酒店二楼凌波厅 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有 股份情况： 表决方式符合《公司法》及《漳州片仔癀药业股份有限公司章程》 （以下简称"《公司章程》"）的规定，公司董事黄进明先生主持本次 会议。大会采用网络投票和现场投票相 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-012 漳州片仔癀药业股份有限公司 关于参加福建辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，漳州片仔癀药业股份有限公 司（以下简称"公司"）将参加由福建证监局、福建省上市公司协会 与深圳市全景网络有限公司联合举办的"2023 年福建辖区上市公司 投资者网上集体接待日活动"。现将相关事项公告如下： 本次集体接待日活动将采用网络远程的方式举行，投资者可以登 录"全景路演"网站（http://rs.p5w.net/），或关注微信公众号"全 景财经"，或下载全景路演 APP，参与本次互动交流。 活动时间为 2023 年 5 月 15 日（星期一）16:00 至 17:30。 届时，公司高管将在线就公司 2022 年度及 2023 年第一季度的业 绩情况、公司治理、发展战略、经营状况和可持续发展等投资者关心 的问题，与投资者进行沟通与交流。 欢迎广大投资者踊跃参与！ 特此公告。 漳 ...

2023年第一季度报告 证券代码：600436 证券简称：片仔癀 漳州片仔癀药业股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Financial Performance - The company's operating revenue for 2022 was CNY 8,694,001,504.35, an increase of 8.38% compared to CNY 8,021,550,451.33 in 2021[12]. - The net profit attributable to shareholders of the listed company was CNY 2,472,344,731.55, reflecting a growth of 1.66% from CNY 2,431,899,933.57 in the previous year[12]. - The net cash flow from operating activities surged to CNY 6,873,030,580.06, a significant increase of 1,386.79% compared to CNY 462,272,404.86 in 2021[12]. - The total assets at the end of 2022 reached CNY 14,603,844,518.45, marking a 16.63% increase from CNY 12,521,151,432.34 at the end of 2021[12]. - The net assets attributable to shareholders of the listed company were CNY 11,329,967,292.12, up 16.74% from CNY 9,705,456,064.61 in 2021[12]. - The basic earnings per share for 2022 was CNY 4.10, an increase of 1.74% from CNY 4.03 in 2021[13]. - The weighted average return on net assets decreased to 23.50%, down 4.18 percentage points from 27.68% in the previous year[13]. - The company distributed cash dividends of CNY 754,146,512.50, accounting for 30.50% of the net profit attributable to shareholders[2]. - The company achieved total revenue of 8.694 billion RMB in 2022, an increase of 8.38% year-on-year[38]. - Net profit for the year was 2.523 billion RMB, reflecting a growth of 2.36% compared to the previous year[38]. Revenue and Profit Trends - Total revenue for Q1 2022 was RMB 234,814.28 million, with a net profit attributable to shareholders of RMB 68,928.91 million[15]. - In Q2 2022, total revenue decreased to RMB 207,448.93 million, while net profit attributable to shareholders was RMB 62,507.52 million[15]. - Q3 2022 saw a revenue of RMB 219,313.80 million and a net profit of RMB 73,812.51 million, indicating a recovery from Q2[15]. - Total revenue reached RMB 867,447.81 million, with a year-on-year increase of 8.37%, while total costs amounted to RMB 471,351.08 million, reflecting a year-on-year increase of 19.53%[44]. - The total gross margin for the company was 45.66%, which decreased by 5.07 percentage points compared to the previous year[44]. Research and Development - The company invested 230,034,488.96 yuan in R&D, which is 2.65% of total revenue[56]. - R&D expenses increased by 15.30% year-on-year, reflecting the company's commitment to enhancing its research capabilities[58]. - The company's R&D investment for the reporting period was CNY 23,003.45 million, representing a year-on-year increase of 15.30%[84]. - The R&D investment accounted for 2.65% of the company's operating revenue, while the parent company's R&D investment accounted for 5.24%[84]. - The company has several major R&D projects, including innovative research on modern disease spectra with an investment of CNY 6,524.83 million, which represents 0.75% of operating revenue[85]. Market and Product Development - The company is focusing on the modernization of traditional Chinese medicine, with over 10 clinical studies on its core product, Pizhonghuang, particularly for cancer treatment[20]. - The company is advancing clinical research on Pizhonghuang to establish new indications, including its use in liver cancer treatment[20]. - A total of 40 research projects are underway related to Pizhonghuang, covering pharmacology, efficacy, and toxicology[20]. - The company is committed to enhancing its governance and compliance through various initiatives, including anti-corruption education and supervision[20]. - The company is focusing on transforming its marketing model and precise market positioning to gain a competitive edge in the pharmaceutical industry[69]. Corporate Governance and Compliance - The company has established a comprehensive internal control system, resulting in the eighth edition of the "Management System Compilation" and "Internal Control Manual" to improve operational efficiency[111]. - The company has maintained independence from its controlling shareholder in business, personnel, assets, and finance, ensuring no interference in decision-making[114]. - The company has implemented measures to ensure compliance with legal and regulatory requirements in its governance structure, with no significant discrepancies noted[113]. - The company has successfully elected new directors and supervisors during the annual general meeting, ensuring governance continuity[117]. - The board of directors has established a performance evaluation system for senior management, ensuring accountability and oversight[153]. Environmental and Social Responsibility - The company achieved a 100% compliance rate in environmental monitoring and a 100% guarantee rate for environmental funding in 2022, with all "three wastes" emissions below national standards[29]. - The company has established an environmental protection mechanism and invested 4.57 million RMB in environmental protection during the reporting period[159]. - The company has implemented a comprehensive environmental monitoring plan, with third-party verification of pollutant emissions[171]. - The company has committed to continuous investment in environmental protection and has developed emergency response plans for potential incidents[175]. - The company promotes low-carbon practices among employees, including daily behavior norms and a "clean plate" campaign to reduce waste[176]. Strategic Initiatives and Future Outlook - The company plans to enhance its cosmetics brand strategy with a focus on long-termism and product innovation[34]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan earmarked for potential deals[120]. - The company is positioned to benefit from the ongoing reforms in centralized drug procurement, which are expected to have a profound impact on the pharmaceutical industry[68]. - The company aims to expand its product pipeline and actively engage in the health product market[68]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[120].